Critical serum creatinine values in very preterm newborns

PLoS One. 2013 Dec 30;8(12):e84892. doi: 10.1371/journal.pone.0084892. eCollection 2013.

Abstract

Background: Renal failure in neonates is associated with an increased risk of mortality and morbidity. But critical values are not known.

Objective: To define critical values for serum creatinine levels by gestational age in preterm infants, as a predictive factor for mortality and morbidity.

Study design: This was a retrospective study of all preterm infants born before 33 weeks of gestational age, hospitalized in Nantes University Hospital NICU between 2003 and 2009, with serum creatinine levels measured between postnatal days 3 to 30. Children were retrospectively randomized into either training or validation set. Critical creatinine values were defined within the training set as the 90(th) percentile values of highest serum creatinine (HSCr) in infants with optimal neurodevelopmental at two years of age. The relationship between these critical creatinine values and neonatal mortality, and non-optimal neural development at two years, was then assessed in the validation set.

Results and conclusion: The analysis involved a total of 1,461 infants (gestational ages of 24-27 weeks (n=322), 28-29 weeks (n=336), and 30-32 weeks (803)), and 14,721 creatinine assessments. The critical values determined in the training set (n=485) were 1.6, 1.1 and 1.0 mg/dL for each gestational age group, respectively. In the validation set (n=976), a serum creatinine level above the critical value was significantly associated with neonatal mortality (Odds ratio: 8.55 (95% confidence interval: 4.23-17.28); p<0.01) after adjusting for known renal failure risk factors, and with non-optimal neurodevelopmental outcome at two years (odds ratio: 2.06 (95% confidence interval: 1.26-3.36); p=0.004) before adjustment. Creatinine values greater than 1.6, 1.1 and 1.0 mg/dL respectively at 24-27, 28-29, 30-32 weeks of gestation were associated with mortality before and after adjustment for risk factors, and with non-optimal neurodevelopmental outcome, before adjustment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Creatinine / blood*
  • Female
  • Follow-Up Studies
  • Gestational Age*
  • Humans
  • Incidence
  • Infant, Extremely Premature / blood*
  • Infant, Newborn
  • Male
  • Renal Insufficiency / blood*
  • Renal Insufficiency / mortality
  • Retrospective Studies
  • Risk Factors

Substances

  • Creatinine

Grant support

The LIFT cohort is supported by grants from the Regional Health Agency of Pays de la Loire. The sponsor has no role in this manuscript.